Search

Your search keyword '"Boursier, Jerome"' showing total 411 results

Search Constraints

Start Over You searched for: Author "Boursier, Jerome" Remove constraint Author: "Boursier, Jerome"
411 results on '"Boursier, Jerome"'

Search Results

2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

3. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

5. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms

7. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

10. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

12. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

13. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

14. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients

15. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

17. A global research priority agenda to advance public health responses to fatty liver disease

18. Extracellular vesicles are carriers of adiponectin with insulin-sensitizing and anti-inflammatory properties

19. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

20. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

22. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications

23. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

24. WED-227 Transient elastography performance for the diagnosis of liver fibrosis in MASLD is independent of steatosis level as determined by MRI proton density fat fraction in a prospective multicentrer study

26. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

28. THU-503 Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease (MASLD): multicenter study comparing patients with or without underlying cirrhosis

29. LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial

30. WED-224 Screening for liver fibrosis in tertiary care using automatic calculation of FIB4 in patients at-risk of diabetes

31. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)

33. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

34. Reliability Criteria of Two-Dimensional Shear Wave Elastography: Analysis of 4277 Measurements in 788 Patients

35. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study

41. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

42. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

43. Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis

44. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

46. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

47. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

48. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

50. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD

Catalog

Books, media, physical & digital resources